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ABSTRACT 
 
Gelatinase B/ matrix metalloproteinase-9 (MMP-9) (EC 3.4.24.35) cleaves many substrates 
and is produced by most cell types as a zymogen, proMMP-9, in complex with the tissue 
inhibitor of metalloproteinases-1 (TIMP-1). Natural proMMP-9 occurs as monomers, 
homomultimers, and heterocomplexes, but our knowledge about the overall structure of 
proMMP-9 monomers and multimers is limited. We investigated biochemical, biophysical, 
and functional characteristics of zymogen and activated forms of MMP-9 monomers and 
multimers. In contrast to a conventional notion of a dimeric nature of MMP-9 
homomultimers, we demonstrate that these are reduction-sensitive trimers. Based on the 
information from electrophoresis, atomic force microscopy (AFM) and transmission electron 
microscopy (TEM), we generated a 3D structure model of the proMMP-9 trimer. Remarkably, 
the proMMP-9 trimers possessed a 50-fold higher affinity for TIMP-1 than the monomers. In 
vivo, this finding was reflected in a higher extent of TIMP-1 inhibition of angiogenesis 
induced by trimers versus monomers. Our results show that proMMP-9 trimers constitute a 
novel structural and functional entity that is differentially regulated by TIMP-1. 
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Summary statement: We have discovered a homotrimeric protease form of gelatinase 
B/matrix metalloproteinase-9 (MMP-9) and showed that the angiogenic activity of MMP-9 
trimers is more tightly controlled by the natural inhibitor TIMP-1 than that of monomers.  
These findings open new roads for selective inhibition of MMP-9. 
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INTRODUCTION 
At present, matrix metalloproteinase-9 (MMP-9/gelatinase B) is becoming one of the most 
studied enzymes in biology, immunology and medicine [1]. MMP-9 has been defined as a 
molecular trigger of the angiogenic switch in cancer progression [2] and is the most complex 
member of the entire MMP family in terms of protein domain structure. In contrast to the 
structure of MMP-2 (MMP-2/ gelatinase A), which is fully resolved [3], the structure of full-
length MMP-9 zymogen (proMMP-9) remains elusive in part because proMMP-9 naturally 
occurs as monomers, heterocomplexes and homomultimers.  
MMP-9 monomers are highly flexible entities. This flexibility is attributed to a central 54-
residue proline- and glycine-rich O-glycosylated (OG) domain that bridges the catalytic 
enzyme core and the hemopexin domain, allowing the terminal domains to act independently 
of each other (Figures 1A and 1B) [1, 4]. Moreover, it was suggested that this feature is 
crucial for the translocation of MMP-9 along collagen fibrils [5].  
The neutrophil gelatinase B-associated lipocalin (NGAL)-MMP-9 heterocomplex is a typical 
product of neutrophils, a unique cell type that does not synthesize MMP-2 or TIMP-1 [6-7]. 
Interestingly, tissue macrophages can alter their phenotype: whereas M1-polarized 
macrophages produce proMMP-9 in complex with TIMP-1, M2-polarized macrophages and 
tumor-associated macrophages produce TIMP-1-deficient proMMP-9, which renders it with 
high angiogenic capacity [8,9]. 
Neutrophils, macrophages and other cell types often produce homomultimers of MMP-9. 
Homomultimerization of MMP-9 involves cysteine bridge formation as indicated by the 
disintegration of multimers into monomers after chemical reduction [6, 10]. Two supposedly 
free cysteines in the monomeric proMMP-9 are located in the center of the OG domain and 
the fourth blade of the hemopexin domain (Figure 1A) [1]. Based on the crystal structure of 
the recombinant hemopexin domain of proMMP-9, it has been assumed that the latter cysteine 
is buried and not accessible for cysteine bridging [11]. This theoretical rationale has provided 
the basis for a common view that homomultimers are dimers (vide infra). Molecular modeling 
based on sedimentation data, suggests that two free cysteines in a proMMP-9 monomer form 
an intramolecular cysteine bridge between the OG and hemopexin domains [12] (Figure 1B). 
In several studies, proMMP-9 homomultimers have been designated as dimers [11, 13-15]. 
However, experimental evidence of the actual structure of MMP-9 homomultimers is only 
circumstantial. There is also a paucity of studies addressing the possible functions of MMP-9 
monomers versus homomultimers in physiological processes [13-15]. This study was 
conducted to identify the molecular structure of proMMP-9 homomultimers and to establish 
their unique in vitro and in vivo biological functions. 
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MATERIALS AND METHODS 
 
Protein production and purification  
A catalytically inactive mutant of proMMP-9 with the catalytic Glu402 mutated into Ala 
(proMMP-9 MutE) and wild-type (WT) proMMP-9 were expressed in Sf9 insect cells and 
purified by gelatin-Sepharose chromatography as previously described [12, 16]. In contrast to 
catalytically active WT proMMP-9, proMMP-9 MutE remained intact after prolonged 
incubation at room temperature, thereby facilitating structure-function studies. When 
necessary, WT proMMP-9 was activated with the catalytic domain of MMP-3 as previously 
described [17]. Recombinant human TIMP-1 was purchased and handled according to the 
manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). 
 
Separation of proMMP-9 monomers and multimers  
The proMMP-9 monomers and multimers were separated by glycerol gradient 
ultracentrifugation. Prior to centrifugation, 12 ml polyallomer tubes (Thermo Scientific, 
Waltham, MA, USA) were coated with Sigmacote® (Sigma, St. Louis, MO, USA). Dilutions 
of 20%, 25% and 30% glycerol were prepared in assay buffer (0.1M Tris-HCl pH 7.4, 0.1M 
NaCl, 10 mM CaCl2) and an equal volume of each solution was applied per polyallomer tube. 
Subsequently, 100 µg of proMMP-9 was loaded on each gradient. Ultracentrifugation (Sorvall 
WX Ultra 80 ultracentrifuge and TH-641 swinging bucket rotor, Thermo Scientific, Waltham, 
MA, USA) was executed for 46 h at 300 000 x g. After centrifugation, the fractions were 
collected (from bottom to top) with the use of a peristaltic pump (Minipuls 3, Gilson, 
Middleton, WI, USA) connected to a fraction collector (model 2128, Bio-Rad, Hercules, CA, 
USA). The fractions were analyzed for protein content and the positions of the proMMP-9 
MutE monomer and multimer peak fractions were determined with the method of Bradford 
[18]. Next, the fractions containing monomeric or trimeric proMMP-9 were pooled and 
subjected to ultrafiltration in Vivaspin 4 concentrators with a cut-off-value of 30 kDa 
(Sartorius Stedim Biotech, Göttingen, Germany). Glycerol buffer was replaced by assay 
buffer. Finally, the concentration and purity of proMMP-9 preparations were determined by 
absorbance at 280 nm and SDS-PAGE analysis. 
 
SDS-PAGE, zymography and Western blot analysis  
Where indicated, proMMP-9 was analyzed by PAGE. We used a discontinuous buffer system 
with a 5% PAA stacking gel and a 7.5% polyacrylamide resolving gel in Tris-HCl/pH 6.8 and 
Tris-HCl/pH 8.8 buffer, respectively. For the analysis of high-molecular weight proMMP-9 
forms, the ProSieve® 50 gel solution (Lonza Group Ltd, Basel, Switzerland) with a 
Tris/glycine buffer system was used. The protein bands were detected by Coomassie brilliant 
blue staining. The gels were further analyzed with ImageJ software [19]. The retention factors 
for individual marker-proteins (HiMark, Invitrogen Ltd, Paisley, UK) were plotted against the 
logarithm of their corresponding molecular weights [20], allowing then to determine the 
retention factor (Rf) for each of analyzed proteins. Next, zymography analysis was performed 
as detailed elsewhere [21]. Western blot analysis was performed with the use of an antibody 
against human MMP-9, as previously described [8]. 
 
Redox experiments  
Purified proMMP-9 MutE monomers, at a concentration of 2 µM, were incubated at 37°C 
with increasing concentrations (0.03 mM, 0.3 mM, 3 mM, and 30 mM) of GSH and GSSG. 
All dilutions were prepared in 150 mM Tris buffer (pH 8.6) based on the conditions 
 
 
5 
previously established for the correct folding of chemokines [22]. At multiple time points, 
samples were analyzed by SDS-PAGE on non-reducing 7.5% Prosieve® 50 gels stained with 
Coomassie brilliant blue. 
 
Glycan analysis 
N-glycans were released from gelatinase B samples by in situ digestion with N-glycosidase F 
(PNGase F, Prozyme) in-gel-blocks as previously described [23]. Briefly, samples were 
reduced and alkylated, set into SDS-gel blocks and washed. Following N-glycans release by 
PNGase F, O-glycans were released by ammonia-based β-elimination [24], and fluorescently 
labelled with 2-aminobenzamide (2AB) by reductive amination [25] (LudgerTag 2-AB 
labeling kit, LudgerLtd., Abingdon, UK). All enzymes were purchased from Prozyme. The 
2AB-labelled glycans were digested for 18 h at 37°C in 10 µl of 50 mM sodium acetate 
buffer, pH 5.5, supplemented with the following enzymes: ABS -Arthrobacter ureafaciens 
sialidase (EC 3.2.1.18), 1 U/ml; BTG - bovine testes β-galactosidase (EC 3.2.1.23), 1 U/ml; 
and BKF – bovine kidney α-fucosidase (EC 3.2.1.51), 1 U/ml. After incubation, the enzymes 
were removed by filtration through protein binding EZ filters (Millipore Corporation, 
Bedford, MA, USA), and the N-glycans were analyzed by HILIC. HILIC was performed 
using a TSK-Gel Amide-80 4.6 x 250 mm column (Anachem, Luton, UK) on a 2695 Alliance 
separations module (Waters, Milford, MA, USA) equipped with a Waters temperature control 
module and a Waters 2475 fluorescence detector. Solvent A was 50 mM formic acid adjusted 
to pH 4.4 with ammonia solution. Solvent B was acetonitrile. The column temperature was set 
to 30°C. Conditions used were as follows (180-min method): a linear gradient of 20 to 58% 
solvent A at a flow rate of 0.4 ml/min over 152 min, followed by 3 min at 58–100% A, then 
increasing the flow rate to 1 ml/min for 5 min at 100% A, returning to 20% A over 1 min, 
running at 20% A for 14 min at 1 ml/min, then returning to 0.4 ml/min over 1.5 min, finishing 
with 1.5 min flow at 20% A, giving a total run time of 180 min [26]. Fluorescence was 
measured at 420 nm with excitation at 330 nm. The system was calibrated using an external 
standard of hydrolyzed and 2AB-labeled glucose oligomers to create a dextran ladder, as 
described previously [23]. 
 
Atomic force microscopy (AFM)  
Freshly cleaved Mica (Ted Pella, Inc., USA) was incubated with 0.5 % (3-
aminopropyl)triethoxysilane (APTES, 99 %; Sigma Aldrich, Israel) in toluene (analytical 
grade; Frutarom, Israel) for 10 min and successively rinsed with 3× 200 µl of absolute ethanol 
(Bio-Lab, Israel), 3× 200 µl of acetone (99.5 %; Mallinckrodt Chemicals, USA) and 3× 200 
µl of ethanol. The amine functionalized Mica surface was gently dried in air flow for 1 min 
and activated by incubation with 6 % glutaraldehyde in 100 mM Tris-HCl buffer, pH 9.0, for 
30 min [27]. The Mica substrate was rinsed with water (10× 200 µl) and gently dried for 1 
min. 10 µl aliquots (2.8 mg ml–1) of purified proMMP-9 multimers in 100 mM Tris-HCl 
buffer, pH 7.4, supplemented with 100 mM NaCl and 10 mM CaCl2, were incubated on 
activated Mica for 1 h at room temperature. The Mica substrate was rinsed with water (10× 
200 µl) and dried under a gentle flow of nitrogen gas for 3 min. Five separate areas of the 
Mica surface were examined by AFM to ensure that a representative sample of the structures 
on the Mica was obtained. Images were collected at a MultiMode AFM with a Nanoscope V 
controller (Veeco Metrology LLC, USA) and acquired with an E-scanner in soft tapping 
mode at room temperature (22–24°C). All images were recorded at a scan rate of 1–3 Hz 
using silicon microcantilevers (OMCL-AC160TS-W2, Olympus, Japan) with a spring 
constant of ~42 N m–1 and a resonant frequency of ~300 kHz (manufacturer specified). The 
target amplitude was 300 mV with a set point of 220–250 mV. Images were acquired in 
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different scan directions and at different length scales to verify the consistency of the 
observed structures. Image processing was performed across the whole image. AFM images 
were processed by a first order flattening. Thereby, all protein molecules were excluded prior 
to background flattening. Profiles of proMMP-9 multimers were acquired from the AFM 
images and the dimensions of the multimers were evaluated. The heights and extensions were 
calculated, binned, normalized, and plotted using OriginPro 9 (OriginLab Co., USA). For 
accurate height determination, the proMMP-9 multimers were cropped from the AFM images 
and the image was brought to a uniform level by a plane fit. The height of proMMP-9 
molecules was determined relatively to the height of the background and indicated by a color 
scale bar. 
 
Transmission electron microscopy (TEM) 
5 µL of proMMP-9 multimer (2.8 mg ml–1) in 100 mM Tris-HCl buffer, pH 7.4, containing 
100 mM NaCl and 10 mM CaCl2, were deposited onto carbon coated copper grids, incubated 
for 1 min and stained with 1% (w:v) aqueous uranyl acetate for 30 s. The samples were 
observed in a Tecnai 12 Transmission Electron Microscope (FEI, Eindhoven, The 
Netherlands), operated at 120 kV. Micrographs were taken with a MegaView III CCD camera 
(SIS, Münster, Germany). 
 
Molecular modeling  
For the molecular modeling of trimeric proMMP-9 we used a previous model established for 
monomeric proMMP-9 [12]. Based on the TEM measurements, four hexagons with different 
diameters were applied to encompass correspondingly, the minimal and maximal diameters of 
small conformers and the minimal and maximal diameters of large conformers. By using the 
assisted model building with energy refinement (AMBER) software, the N-terminal and C-
terminal lobes of three molecules of monomeric proMMP-9 were placed on the corners of 
these hexagons. Next, the flexible O-glycosylated domain was bent so that intermolecular 
bridges could be formed between Cys468 and Cys674. 
 
Surface plasmon resonance (SPR)  
A 1:1 mixture of 0.2 M N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide and 0.05 M N-
hydroxysuccimide in water was used to activate Biacore sensor chips type CM513. TIMP-1 
was immobilized at 10 µg/ml in 10 mM sodium acetate, pH 4.5. LRP-1 was immobilized at 
15 µg/ml in 10 mM sodium acetate, pH 3.0. LRP-2/Megalin was immobilized at 10 µg/ml in 
10 mM sodium acetate, pH 4.5. The remaining binding sites were blocked with 1 M 
ethanolamine, pH 8.5. The resulting receptor densities were 70 fmol TIMP-1/mm², 31 fmol 
LRP-1/mm² and 25 fmol LRP-2/megalin/mm². A control chip underwent only the activation 
and blocking procedures. ProMMP-9 monomer and trimer samples were diluted and analyzed 
at various concentrations in 100 mM Tris/HCl, 100 mM NaCl, 10 mM CaCl2 and 0.005% 
Tween-20 pH 7.4. After each analysis the sensory chips were regenerated with 1.6 M glycine-
HCl pH 3.0. The analyses were performed on a Biacore 3000 instrument (Biacore, Sweden), 
and the response was expressed in relative response units [12].  
 
Cell adhesion assay  
96-Well plates were coated with proMMP-9 monomers or multimers, complexed with or 
without TIMP-1. The proMMP-9 monomers or multimers were used at increasing quantities 
(from 140 ng to 560 ng per well). When TIMP-1 was added (45 ng per well), the samples 
were first pre-incubated (30min, 37°C) to allow the formation of proMMP-9/TIMP-1 
complexes. Control plates were coated with 0.5% BSA. Bone marrow cells (1 × 105), freshly 
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collected from MMP-9 knockout (KO) mice [28], were fluorescently labeled with 1.4 ng/ml 
2,7-bis(carboxyethyl)-5(6)-carboxyfluorescein-acetoxymethyl ester (BCECF-AM, Molecular 
Probes, CA, USA) for 20 min. The labeled cells were washed to eliminate free dye, suspended 
in adhesion medium (RPMI 1640, 0.5% BSA), and added to the coated wells at 1x105 cells 
per well. After 60 min at 37 °C, attached cells were lysed with 0.1% SDS in PBS and 
fluorescence was quantified using an FL600 Microplate fluorescence reader (Biotek, 
Winooski, USA) [29]. 
 
Chick embryo chorioallantoic membrane (CAM) angiogenesis model  
The CAM angiogenesis assays were performed as previously described in detail [30-31]. An 
angiogenic index was determined within 72 to 96 h for each 3D-collagen graft as the fraction 
of grids with newly formed blood vessels over the total number of grids scored. 
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RESULTS 
 
Production and fractionation of proMMP-9 monomers and multimers  
We investigated various forms of recombinant proMMP-9 and found that a catalytically 
inactive mutant of proMMP-9, proMMP-9 MutE, was optimal for structural studies because 
of enhanced protein stability and absence of autocatalysis. Analogous to human MMP-9 
forms in vivo, when expressed in insect cells, proMMP-9 is produced as both monomers and 
homomultimers [12]. Following optimization of preparative isolation protocols, we achieved 
a good separation of monomers and multimers by glycerol gradient ultracentrifugation (Figure 
1C) and produced and purified proMMP-9 monomeric and multimeric forms for further 
structural, biochemical and biological characterization (Figure 1D). Separation of WT species  
confirmed that production and purification of proMMP-9 were reproducible and yielded 
consistent ratios of monomers and multimers as judged by SDS-PAGE and gelatin 
zymography (Figures 1D and 1E).  
 
Electrophoretic analysis of proMMP-9 monomers and multimers 
The original proMMP-9 preparations contained approximately 70% monomers and 30% 
multimers (Figure 2A). In addition, when subjected to reducing conditions, multimeric 
proMMP-9 was completely reduced into monomers (Figure 2B). Because no reliable protein 
size markers exceeding the apparent molecular weights (>200 kDa) of dimers were included 
in previous studies [6, 15], we performed a regression analysis of electrophoretic separation 
data based on protein standards, which included 250 and 500-kDa mol. wt. markers (Figures 
2C and 2D). Although some variations were observed among 60 independent, weekly-
produced batches of proMMP-9, the apparent molecular weight of multimers repeatedly 
situated between dimers and trimers. The frequency distribution of monomers was less 
skewed than that of the multimers (Figure 2E). Statistical analysis (Figure 2F) yielded 89.3 ± 
6.78 kDa for the monomers and 228.3 ± 18.1 kDa for the multimers [median ± interquartile 
range (IQR)]. Based on the specific molecular weight of the marker mixture, the analysis 
yielded a molecular weight ratio of 2.5 for multimers versus monomers, which was exactly 
between trimers and dimers.  
 
In vitro stability of monomeric and multimeric proMMP-9 
We examined whether proMMP-9 multimers can be generated in vitro from the purified 
monomer preparations. No multimeric forms were generated from proMMP-9 monomers 
following a series of oxido-reduction pair reaction cycles known to induce proper folding and 
double cysteine bridge formation of chemokines [22]. Hence, it is plausible to conclude that 
multimerization occurs naturally during cell-mediated production of proMMP-9 and is not 
artificially triggered during biochemical purifications. In line with previous findings [10], 
chemical reduction of pure multimers with β-mercaptoethanol yielded exclusively monomers 
(Figure 2B), attesting that the multimer is formed by cysteine bridging.  
 
Structural analysis of monomeric and multimeric proMMP-9 
We investigated whether monomeric proMMP-9 molecules, having certainly one and possibly 
two accessible free cysteine sulfhydryl groups, form dimers, trimers or other multimers. AFM 
was used to visualize individual multimers (Figures 3A to 3D). The majority of proMMP-9 
multimers appeared as circular structures with a height of 4.75 ± 0.63 nm (Figure 3E), similar 
to the known height of proMMP-9 monomers [4]. AFM images indicated the existence of two 
distinct populations of circular proMMP-9 multimers with different sizes. Since the diameter 
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of the AFM probe (ØAFM-tip ~15 nm) has a size similar to that of the diameter of the 
proMMP-9 multimer, the diameter of the latter can be artificially broadened in the x-y-plane 
[32-34]. Thus, we analyzed the large proMMP-9 multimers characterized by an inner 
diameter of 18.8 ± 5.7 nm and an outer diameter of 52 ± 10 nm (Figures 3F and 3G). 
Previously, AFM analysis of proMMP-9 monomers yielded a two-lobed structure with a 
flexible linker, the larger lobe representing the catalytic part and smaller lobe being the 
hemopexin domain [4]. Herein, the high-resolution AFM images of proMMP-9 multimers 
indicated multi-lobed ring structures (Figures 2B to 2D), consistent with a trimeric 
composition of the proMMP-9 multimers. We also analyzed the size of large proMMP-9 
multimers pre-complexed with TIMP-1 and found that the inner and outer diameters of the 
proMMP-9 multimers in complex with TIMP-1 did not significantly differ from the non-
complexed trimers (douter ± SE = 58 ± 13 nm, dinner ± SE = 25.8 ± 4.6 nm, n = 21), probably 
due to dissociation of the proMMP-9/TIMP-1 complex during the AFM preparation 
procedure.  
In accordance with the AFM findings, TEM analysis of proMMP-9 trimers also demonstrated 
that the trimers were represented by large and small circular structures (Figures 4A to 4C). 
Quantitative processing of a total of 868 individual trimers revealed that the large trimers had 
outer diameters of 14.1 ± 2.2 nm and inner diameters of 6.9 ± 0.8 nm, whereas the outer and 
inner diameters of small trimers were respectively 10.8 ± 2.1 nm and 2.8 ± 0.7 nm (Figures 
4D and 4E). The statistical analysis of TEM data indicated that the small and large trimers 
were present at a ratio of 3:1 (see also Figure 4C).  
Trimeric hydrolases are rare in nature and their formation, mediated by protein disulfide 
isomerase, would require at least two free cysteine residues per monomeric form. Fulfilling 
this requirement, there are two possibly free cysteines in the primary structure of proMMP-9 
(Figure 1A). In addition, the cysteine in the OG-domain is located in the very center of this 
highly flexible domain [1], which provides a link between the globular N-terminal catalytic 
segment and the C-terminal hemopexin domain (Figure 1A). Considering structural aspects, 
namely the presence of two free cysteines, flexibility of the OG domain [4], central location 
of the cysteine (Cys468) within the OG domain and the circular structures observed by AFM 
and TEM, we generated a model for trimeric proMMP-9 (Figures 4F to 4H). This model 
depicts how three proMMP-9 monomers can form a circular structure with globular domains 
at the periphery and a central hollow. We indicate how three intermolecular bridges are 
formed between the cysteine (Cys468) in the center of the one OG domain and cysteine 
(Cys674) in the blade of the hemopexin domain of the adjacent molecule, resulting in the 
formation of a trimer (Figure 4G).  
We next attempted to identify the exact cysteines involved in trimerization of proMMP-9 and 
to quantify free cysteines present in monomeric proMMP-9 compared to trimeric proMMP-9. 
However, despite implementation of several independent techniques, including mass 
spectrometry following tryptic digestion used previously [12], we were not able to determine 
the arrangements of disulfide bridges and free cysteines in proMMP-9 monomers and trimers, 
mostly due to extensive N- and O-glycosylation of proMMP-9 molecules. Furthermore, we 
also attempted to determine the amount of free SH groups in monomeric proMMP-9 using 
urea and Ellman’s reagent or Alexa Fluor® 633 C5 Maleimide [35-36]. However, these 
approaches which are suitable for free cysteine quantification in peptides, failed due to 
relatively high molecular weight and complexity of the proMMP-9 molecule. 
 
Glycan composition of monomeric and multimeric proMMP-9 
The proMMP-9 molecule is decorated with both N- and O-linked oligosaccharides [37], 
which define the overall structure of glycoproteins [38, 39]. Therefore, we investigated the 
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possibility that differential glycosylation of individual proMMP-9 monomers may affect their 
ability to form multimers. To test this hypothesis, N- and O-linked glycans present on 
proMMP-9 monomers versus trimers were analyzed by hydrophilic interaction liquid 
chromatography (HILIC) in combination with sequential digestion by an array of 
exoglycosidases. Both forms of proMMP-9 contained the N-linked glycan F(6)M3, as 
indicated by bovine kidney alpha-fucosidase (BKF) digestion (Figure 5A). O-linked glycans 
were subjected to a range of exoglycosidases. For precise assignments, individual peaks 
containing O-glycans were collected and digested with bovine testes β-galactosidase (BTG). 
Both monomeric and trimeric proMMP-9 contained the same core 1 glycans Galβ1-3GalNAc 
and Galβ1-3GlcNAcβ1-3Galβ1-3GalNAc (Figures 5B, 5C and Table 1), and therefore, no 
structural differences were observed between monomer and trimer O-linked glycans. 
 
Binding of monomeric and trimeric proMMP-9 to LRP-1, LRP-2 and TIMP-1. 
In a physiological environment, the majority of different cell types, except of neutrophilic 
granulocytes [6, 7], produce proMMP-9 in complex with its inhibitor, TIMP-1, bound to the 
hemopexin domain of the zymogen. In addition, the bioavailability of proMMP-9 is also 
regulated by the cargo receptors, namely low density lipoprotein receptor-related protein-1 
(LRP-1) and LRP-2/megalin, through their binding to the hemopexin domain of proMMP-9 
[12]. Since the hemopexin domain would be involved in trimerization via its cysteine residue, 
we compared proMMP-9 monomers and trimers for their efficiency to bind TIMP-1, LRP-1 
and LRP-2.  
Monomers and trimers of proMMP-9 MutE at increasing concentrations ranging from 10 nM 
to 200 nM, were tested for their binding efficiency to TIMP-1, LRP-1, or LRP-2 immobilized 
on sensor chips (Figure 6A). The global fit analysis of surface plasmon resonance (SPR) data 
demonstrated a substantial decrease in dissociation rates of TIMP-1 from proMMP-9 trimers, 
indicating a significantly higher affinity between TIMP-1 and proMMP-9 trimers than TIMP-
1 and proMMP-9 monomers, exhibiting the dissociation constants (Kd) of 0.12 nM and 10 
nM, respectively (Figure 6A). A similar differential in affinity to TIMP-1 was also 
characteristic of WT proMMP-9, which demonstrated a dissociation constant (Kd) of 10 nM 
for monomers and a Kd of 0.4 nM for trimers. Importantly, there were no differences in this 
order of magnitude between proMMP-9 monomers versus trimers in their binding strengths to 
LRP-1 or LRP-2/megalin (Figure 6A). We have previously shown that the LRP-1 and LRP-2 
docking sites do not overlap with the TIMP-1 binding site in the MMP-9 molecule, although 
all these sites are located in the hemopexin domain [12]. Therefore, it is plausible to suggest 
that the binding of proMMP-9 to LRPs would not be influenced by pre-complexing of 
proMMP-9 with TIMP-1 and that the uptake of monomeric and trimeric proMMP-9 by cell 
surface LRPs would not be regulated differentially by TIMP-1. 
 
Cell binding properties of monomeric and trimeric proMMP-9 
ProMMP-9 binds to a number of cell surface molecules (e.g. LRP-1, LRP-2, CD44 and 
integrins) and thereby controls cell surface proteolysis and activates outside-in cell signaling 
pathways. Since these interactions are mediated by the hemopexin domain of MMP-9 [40], 
we hypothesized that the efficiency of hemopexin-mediated binding to cell surfaces might be 
different for proMMP-9 trimers.  
To test this hypothesis, we compared the efficiency of cell binding to proMMP-9 MutE 
trimers and monomers immobilized on plastic surfaces.  In a cell adhesion assay employing 
bone marrow cells from MMP-9 KO mice to avoid interference with endogenously produced 
proMMP-9, we found that proMMP-9 MutE trimers and monomers induced similar levels of 
cell adhesion. The cells bound to both proMMP-9 monomers and multimers in a dose-
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dependent manner, and this binding was insensitive to TIMP-1 complexed to proMMP-9 
(Figure 6B). In agreement with the findings that TIMP-1 can interact with cell surface 
molecules, e.g. β1 integrins [41-42], the plastic-bound TIMP-1 also induced cell adhesion, 
albeit at relatively low levels. Since the proMMP-9/TIMP-1 complex was shown to interact 
with CD44 via the hemopexin domain of the MMP-9 molecule [43], the cell binding 
properties of free TIMP-1 and TIMP-1 bound to MMP-9 may vary. 
 
Induction of angiogenesis by monomeric and trimeric proMMP-9 
Since proMMP-9 triggers the angiogenic switch [2] and induces angiogenesis [44], we 
evaluated the angiogenic potential of proMMP-9 monomers and trimers. We previously 
established that in its TIMP-free form, recombinant and neutrophil proMMP-9 (both 
containing mixtures of multimeric and monomeric forms of the zymogen) exhibited a high 
angiogenic activity in vivo [7, 30, 45]. Both the recombinant and neutrophil TIMP-free 
proMMP-9 are proteolytically activated in the tissue microenvironment by either endogenous 
activators of proMMP-9 such as stromal MMP-3 [46] or by conformational activation of 
highly concentrated proMMP-9 bound to stromal matrix components and undergoing 
autoactivation [47]. Then, the proteolytically or conformationally activated MMP-9 enzyme 
could liberate extracellular matrix-bound angiogenic factors such as VEGF and FGF-2, 
making them bioavailable to induce angiogenesis [30].  
Herein, we analyzed and compared the angiogenesis-inducing potency of proMMP-9 
monomers and trimers and their sensitivity to TIMP-1 inhibition in vivo. By employing a 
chick embryo angiogenesis model [31], we found that TIMP-free trimers were capable of 
inducing angiogenesis and that the efficiency of proMMP-9 trimers was comparable with that 
of monomers (Figure 6C). However, the angiogenic response induced by multimers was 
significantly more sensitive to TIMP-1 inhibition than that induced by monomers (Figure 6D). 
This finding indicates that the induction of angiogenesis by MMP-9 trimers could be 
regulated differentially from that by MMP-9 monomers.  
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DISCUSSION 
Metalloproteinases and their inhibitors mediate many biological and pathological processes 
[48 - 50] and, within this family of enzymes, MMP-9 is an outstanding example. Not only did 
the present study provide the first experimental evidence for the molecular nature of MMP-9 
multimers, it also revealed the trimeric structure of MMP-9 as a specific entity that exhibits 
high affinity to TIMP-1. Herein, trimeric MMP-9 was shown to participate in a number of 
biological activities, including binding to cell surfaces and the induction of angiogenesis. The 
following important conclusions can be drawn from our findings: (i) The previously described 
flexibility of monomers [4] now comes into the context of bending and assembly into trimers 
via disulfide bridges. (ii) The ongoing debate about which individual free cysteines, namely in 
the OG domain or in the hemopexin domain, are involved in multimerization [11 - 15], might 
be resolved. In the MMP-9 trimerization process, the cysteines from both the OG and 
hemopexin domains would be involved, analogous to trimeric haptoglobin 2-2, where 2 free 
cysteines in each monomer bridge with 2 free cysteines in the adjacent molecule to form a 
circular multimer [51]. (iii) The finding of a trimeric MMP-9 might shed light on how triple 
helical collagens are being processed in nature. Triple helical collagens are hydrolyzed by 
collagenases (e. g. MMP-1, MMP-8, and MMP-13), into 1/4 and 3/4 length fragments. 
Subsequently, these fragments are further degraded by MMP-2/gelatinase A and MMP-
9/gelatinase B [52, 53]. At the molecular level it is still difficult to understand how such a 
large triple helical substrate can be processed since molecular studies showed that triple 
helical collagens do not fit into the active site of monomeric MMPs [54]. Additionally, 
whether or not MMP-9 digests type I, II and III collagens has been a point of debate [55]. The 
existence of the MMP-9 trimer might better explain how MMP-9 molecules are able to 
accommodate cleaved triple helical collagen fragments. (iv) Our findings are particularly 
interesting for leukocyte biology, because neutrophils [6, 7] and M2-polarized macrophages 
and tumor-associated macrophages [8,9] uniquely produce TIMP-free proMMP-9. However, 
only neutrophils produce copious quantities of proMMP-9 abundant in trimers without TIMP-
1, which could uniquely serve as quick TIMP-1 trap, allowing the less sensitive MMP-9 
monomers to induce angiogenesis. In addition, from the moment that TIMP-1 is secreted into 
the micro-environment by cell types different from neutrophils, the catalysis by trimers would 
be shut down first, leaving the monomers still active. With more TIMP-1 being produced at 
later stages, all MMP-9 activity would become inhibited. This aspect could be critical for all 
physiological and pathological conditions such as cancer [49, 56], inflammation [48, 57] and 
angiogenesis [7, 45], where neutrophils play key roles associated with the delivery of TIMP-
free proMMP-9. 
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Figure Legends 
Figure 1    Separation of proMMP-9 monomers and multimers  
(A) Primary structure of full-length human proMMP-9 with indication of protein domains, 
cysteine sulfhydryl (S) groups, the propeptide cysteine switch (orange dotted line) and 
cysteine bridges (red dotted lines). (B) Scaled, schematic model representation of the 
proMMP-9 monomer, including the propeptide (green), the fibronectin like domain (blue), the 
Zn2+-binding domain (orange), the catalytic domain (yellow), the flexible OG domain (black) 
and the hemopexin-like domain (red). In the atomic model the central cysteine in the OG-
domain is bridged to the free cysteine in the hemopexin domain [12]. (C) Separation of 
proMMP-9 MutE monomers and multimers by ultracentrifugation. The graph shows the 
relative absorbance obtained for each fraction collected from a single tube after 
ultracentrifugation (top). Two absorbance peaks were detected, consistent with the separation 
of proMMP-9 MutE multimers and monomers. The purity of each fraction was determined by 
SDS-PAGE (bottom). (D) Zymography (left) and SDS-PAGE (right) analysis of the WT 
proMMP-9 and MutE proMMP-9 separated by ultracentrifugation. The right lane contains a 
set of standard proteins with known molecular masses, indicated in kDa. (E) Separation of 
recombinant human WT proMMP-9 and zymography analysis of each fraction collected from 
a single tube after ultracentrifugation. 
Figure 2    Electrophoretic analysis of proMMP-9 monomers and multimers 
(A) Percentage (mean ± SD) of monomers (69.7 ± 4.6%) and multimers (30.3 ± 4.6%) in 
independent batches (n = 50) of proMMP-9, purified from Sf9 cells cultures. Relative 
amounts of monomers and multimers were determined by Coomassie brilliant blue staining 
and expressed as percentage of total protein content. Grey lines indicate the mean values. (B) 
Electrophoretic separation and Coomassie brilliant blue staining of a proMMP-9 trimer 
preparation. Upon chemical reduction with β-mercaptoethanol, proMMP-9 trimers migrated 
to a similar position as monomers. (C) Western blot analysis of two recombinant proMMP-9 
samples (mixture of proMMP-9 monomers and proMMP-9 trimers). The proMMP-9 
multimers were resolved at the position higher than the 250-kDa molecular weight marker. 
(D) An example of an SDS-PAGE gel with the HiMark® ladder (left) and a mixture of 
proMMP-9 monomers and multimers (right). The gel is complemented with the 
corresponding scanning densitometry analysis performed by using ImageJ software. (E) 
Frequency distribution histograms of proMMP-9 monomers and multimers as determined 
from multiple SDS-PAGE analyses. (F) Box-whisker-plots for the molecular weight 
distribution profiles of proMMP-9 monomers and multimers (90 percentile, 75 percentile, 
median, 25 percentile, 10 percentile and outliers, represented by dots). The median values (± 
IQR) for the monomers and multimers were 89.3 ± 6.8 kDa and 228.3 ± 18.1 kDa, 
respectively. Statistical analysis by two-tailed, non-paired Student’s t-test (P<0.0001), also 
indicates a clear separation of the fractions. 
 
Figure 3    Structural analysis of proMMP-9 trimers by AFM 
(A) Overview image of purified proMMP-9 trimers. Scale bar = 200 nm. Two boxed areas are 
enlarged and presented in images panels B and C. (B – C) zoomed areas. Scale bar = 50 nm. 
The boxed area is magnified and presented in panel D. (D) The proMMP-9 trimer 
demonstrating a multi-lobed composition with a hollow center. The colors have been adjusted 
for contrast enhancement. Scale bar = 20 nm. (E) Histogram depicts distribution of proMMP-
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9 multimers according to their height determined from AFM data (n = 50). The calculated 
height of 4.75 ± 0.63 nm (mean ± SD) is similar to the height of proMMP-9 monomers 
established previously [4]. (F) Histogram depicts distribution of lobe-to-lobe distances within 
monomeric subunits (n = 160), determined from AFM analysis of proMMP-9 trimers. (G) 
Histogram depicts distribution of inner diameters (mean = 18.8 ± 5.7 nm; grey) and outer 
diameters (mean = 52 ± 10 nm; white), determined for proMMP-9 trimers (n = 54).  
 
Figure 4    TEM analysis and molecular model of proMMP-9 trimers  
(A) TEM overview image. The proMMP-9 trimers occur as negatively stained round 
structures. Scale bar, 200 nm. (B) Representative TEM image of proMMP-9 trimers at higher 
magnification. Scale bar, 50 nm. (C) Magnified area from panel B. Two populations of 
proMMP-9 trimers of different sizes are indicated by blue (small conformers) and red (large 
conformers) circles. Scale bar, 20 nm. (D) Statistical analysis of TEM images (n = 868) 
revealed two distinct maxima for the outer (white histogram) and inner (grey histogram) 
diameters, indicating the presence of two size populations of the proMMP-9 trimers. For the 
large conformers of proMMP-9 trimers (red circles in C), an inner diameter of 6.9 ± 0.8 nm 
(mean ± SD) and an outer diameter of 14.1 ± 2.2 nm have been obtained. For the small 
conformers (blue circles in C), an inner diameter of 2.8 ± 0.7 nm and an outer diameter of 
10.8 ± 2.1 nm have been obtained. The colored curves indicate distribution of small (blue) 
and large (red) conformers. (E) Histogram, distribution of the ratios between the outer and 
inner diameters of proMMP-9 trimers. Mean = 2.84 ± 0.82. (F-H) Molecular models of 
trimeric proMMP-9. The models assume that the Cys468 and Cys674 are involved in 
trimerization. (F) Model of trimeric proMMP-9 based on the AFM and TEM data. Hexagons 
indicate the inner minimal and the outer maximal diameters of the large (red) and small (blue) 
proMMP-9 conformers. (G) 3D model of a proMMP-9 trimer. A space filling model (left 
panel) and a cartoon model (right panel) with the three monomers in different colors, illustrate 
the intermolecular cysteine bridges (in yellow) between the monomers. (H) A space filling 
model (left panel) and a cartoon model (right panel) depicting the functional domains of 
proMMP-9 in the trimeric structure. The same color code was adopted as used in Figure 1. 
The molecular orientations are the same as in panel G. 
 
 
Figure 5   Glycan analysis of proMMP-9 monomers and trimers 
(A) N-linked glycans of separated proMMP-9 monomer and trimer preparations were isolated 
and analyzed by HILIC. Typical profiles of undigested and BKF-digested monomeric and 
trimeric proMMP-9 N-glycomes are shown. (B, C) Typical HILIC profiles of monomeric and 
trimeric proMMP-9 O-glycomes before and after digestion with a range of exoglycosidases. 
Peaks were collected and each digested with BTG and/or ABS. Structural symbols for the 
glycans and their linkages are shown in the box situated at the bottom of the figure. These 
symbols are also the keys to the structures shown in Table 1. 
 
Figure 6    Functional analysis of trimeric proMMP-9 
(A) SPR binding of proMMP-9 monomers and trimers to TIMP-1, LRP-1 and LRP-2 
(megalin). The y-axis indicates the difference between the sample and control runs in relative 
response units. The functional affinity of proMMP-9 monomers to TIMP-1 was 
approximately 50 times less than that of the proMMP-9 trimers. The binding affinity of 
monomeric proMMP-9 MutE to LRP-1 and LRP-2 was slightly higher than the binding 
affinity of the trimers. (B) Cell adhesion assays. Binding of bone marrow cells isolated from 
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MMP-9 KO mice to proMMP-9 monomers and trimers. Increasing quantities of monomers 
and trimers (140 ng to 560 ng) were tested in the presence or absence of TIMP-1 (45 ng). (C) 
Angiogenic capacity of purified proMMP-9 monomers (blue), proMMP-9 trimers (red) and 
neutrophil-derived proMMP-9 (orange). Monomers and trimers of proMMP-9 were compared 
in the CAM angiogenesis model. 3-D collagen grafts, containing gridded meshes, were 
supplemented with proMMP-9 monomers, proMMP-9 trimers, or neutrophil-derived 
proMMP-9 (1 or 3 ng per graft). In the negative control, the grafts were supplemented with 
PBS only (black). Collagen grafts were placed on the CAM of chick embryos (5-6 grafts per 
embryo; 5-6 embryos per variant). The levels of angiogenesis were quantified as angiogenic 
index (the ratio of grids containing newly formed blood vessels versus total number of 
evaluated grids). Horizontal lines indicate medians. (D) TIMP-1 inhibition of angiogenesis 
induced by proMMP-9 monomers (blue, n=43), trimers (red, n=44) and neutrophil-derived 
MMP-9 (orange, n=20) preparations. CAM angiogenesis assay was performed as described in 
C. Monomers and trimers of proMMP-9 were supplemented at 3 ng per graft, alone or with 10 
ng of recombinant TIMP-1. Negative control contained PBS only (black, n=24). *, ** and 
***, P<0.05, 0.005 and 0.0001, respectively; two-tailed Student’s t-test. 
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Table 1: N- and O-glycans identified in monomeric and trimeric proMMP-9 
 
peak abbreviations structure glucose units 
N-glycans 
 F(6)M3 
 
4.84 
O-glycans 
1 Galβ1-3GalNAc  1.96 
2 Galβ1-3GlcNAcβ1-3Galβ1-3GalNAc 
 
3.5 
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